logo
  

Torchmark Q1 Profit Decreases- Quick Facts

Torchmark Corp. (TMK) reported that its first-quarter net income decreased to $121.6 million from $132.9 million, last year. Earnings per share was $0.95, compared to $0.98 for the year-ago quarter. Net operating income per share was $1.04, for the quarter.

On average, 15 analysts polled by Thomson Reuters expected the company to report profit per share of $1.05 for the quarter. Analysts' estimates typically exclude special items.

Net sales of life insurance increased 17%, while net health sales increased 2%. Excluding group business, net health sales increased 22%. Total insurance premium revenue was $821.4 million, compared to $791.6 million, a year ago.

Torchmark projects that for the year ending December 31, 2015, net operating income per share will be in a range of $4.20 to $4.36. Analysts expect the company to report 2015 earnings per share of $4.30.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
AbbVie (ABBV) Monday announced a collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals, a clinical stage neuroscience biotech firm, to develop next-generation treatment approaches and unmet needs in psychiatric disorders. AbbVie noted that the first-generation compounds may... Healthwest Minerals, Inc. d/b/a Mt. Capra Products has recalled 1,506 boxes of Goat Milk Formula Recipe Kit, also urging consumers to immediately discontinue use of the product as infant formula. The firm does not recommend using this product for infants from 0-12 months of age. Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
Follow RTT